2014 Annual Meeting | 2HC.003 - Multiple Sclerosis Overview I: Basic and Translational Science

Date Sunday 04/27/14

Time 08:00 AM - 12:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Half-Day Course

Director(s) Emmanuelle Waubant, MD, PhD, FAAN

Topic(s) General Neurology

Learning Objectives Participants should be familiar with current concepts of multiple sclerosis pathogenesis with respect to the complex interplay of environmental and genetic contributions to disease susceptibility, how recent findings in epidemiology and neuropathology have changed our thinking about MS, and understand the essential immunological mechanisms involved in MS, and the immunological effects of current disease-modifying treatments.

CME Available No CME available

Recommended Audience Trainee, General Neurologist, Specialist Neurologist

Teaching Styles Didactic

Event Timeline
08:00 AM - 08:05 AM		Introduction to Symposium Emmanuelle Waubant, MD, PhD, FAAN
08:05 AM - 08:45 AM		Neuropathology of Multiple Sclerosis Josa Frischer
08:45 AM - 08:55 AM		Questions and Answers
08:55 AM - 09:35 AM		Genetics and Epidemiology of Multiple Sclerosis Emmanuelle Waubant, MD, PhD, FAAN
09:35 AM - 09:45 AM		Questions and Answers
09:45 AM - 10:05 AM		Break
10:05 AM - 10:50 AM		Neuroimmunology of Multiple Sclerosis Michael K. Racke, MD
10:50 AM - 11:00 AM		Questions and Answers
11:00 AM - 11:45 AM		Immunotherapeutics of Multiple Sclerosis-Mechanisms of Action Lawrence Steinman, MD, FAAN
11:45 AM - 12:00 PM		Questions and Answers

Faculty Disclosures
Emmanuelle Waubant, MD, PhD, FAAN	Dr. Waubant has received personal compensation in the range of $500-$4,999 for serving as a Consultant for emerald pharmaceuticals. Dr. Waubant has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for elsevier. The institution of Dr. Waubant has received research support from NIH. The institution of Dr. Waubant has received research support from NMSS. The institution of Dr. Waubant has received research support from PCORI. The institution of Dr. Waubant has received research support from Race to Erase MS. The institution of Dr. Waubant has received research support from Roche. The institution of Dr. Waubant has received research support from Biogen. The institution of Dr. Waubant has received research support from Department of Defense. Dr. Waubant has received publishing royalties from a publication relating to health care.
Michael K. Racke, MD	Dr. Racke has received personal compensation for serving as an employee of Quest Diagnostics. Dr. Racke has stock in Quest Diagnostics. Dr. Racke has received intellectual property interests from a discovery or technology relating to health care.
Lawrence Steinman, MD, FAAN	Dr. Steinman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Steinman has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for 180 Life Sciences. Dr. Steinman has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for BioAtla. Dr. Steinman has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Pasithea. Dr. Steinman has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Atreca. Dr. Steinman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Steinman has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for National Academy of Sciences. Dr. Steinman has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Gibson Dunn. The institution of Dr. Steinman has received research support from Roche. The institution of Dr. Steinman has received research support from Novartis. Dr. Steinman has received intellectual property interests from a discovery or technology relating to health care.
Josa Frischer	No disclosure on file